Stereotactic Radiosurgery and Erlotinib in Treating Patients With Non-Small Cell Lung Cancer and Brain Metastases

Part of paid clinical trials in San Francisco, California.

Sponsor: University of California, San Francisco
Study ID: NCT00738335
Phase: PHASE1
Status: Withdrawn

Conditions

Lung Cancer
Metastatic Cancer

Eligibility Criteria

Sex: ALL
Age: 18 Years - N/A
Healthy Volunteers: Not accepted

Interventions

erlotinib hydrochloride — DRUG
immunoenzyme technique — OTHER
laboratory biomarker analysis — OTHER
liquid chromatography — OTHER
mass spectrometry — OTHER
pharmacological study — OTHER
stereotactic radiosurgery — RADIATION

Study Details

RATIONALE: Erlotinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Radiation therapy uses high-energy x-rays to kill tumor cells. Stereotactic radiosurgery may be able to deliver x-rays directly to the tumor and cause less damage to normal tissue. Erlotinib may make tumor cells more sensitive to radiation therapy. Giving erlotinib together with stereotactic radiosurgery may kill more tumor cells. PURPOSE: This phase I clinical trial is studying the side effects of erlotinib when given together with stereotactic radiosurgery and to see how well it works in treating patients with non-small cell lung cancer with brain metastases.